Continuing Single-Agent Bevacizumab as Maintenance Therapy After Induction XELOX (or FOLFOX) Plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer

SECTION EDITOR'S NOTE: Metastatic colorectal cancer is the second leading cause of cancer death in the United States. Since 1995, treatment regimens have included capecitabine, irinotecan, oxaliplatin, bevacizumab, cetuximab, panitumumab, aflibercept, and reforafenib. These medications have dou...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Díaz-Rubio, Eduardo, Pietrantonio, Filippo, de Braud, Filippo
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2012
Matèries:
Challenging Cases
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3500363/
https://ncbi.nlm.nih.gov/pubmed/23073991
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0075
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars